Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Ph 2 Study of IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Ph 2 Study of IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
Conditions:   Melanoma Stage III;   Melanoma Stage IV;   Inoperable Disease
Interventions:   Drug: Interleukin-2;   Drug: Ipilimumab;   Drug: Nivolumab
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Clinigen
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 25, 2020 / by / in
Comments